Acute promyelocytic leukaemia
What it is
Acute promyelocytic leukemia is one subtype of acute myeloid leukemia, the M3, and it is defined by its molecular abnormality: PML-RARA, with t(15:17). In the WHO 2016 list of AML and related neoplasms it stands in the group with recurrent genetic abnormalities, written there as APL with PML-RARA, alongside AML with t(8;21) RUNX1-RUNX1T1, AML with inv(16) or t(16;16) CBFB-MYH11, and the rest.
What can go wrong
The one thing that sets APL apart in daily care is bleeding. Acute myeloid leukemia releases a pro-coagulant, and the release of procoagulants leads to DIC, with the higher risk in APL. That is why DIC risk is listed as a key feature of PML-RARA, alongside Auer rods and hypergranular promyelocytes.
How it is diagnosed
FISH for t(15:17) is what marks APL.
The rest of the investigations are the AML investigations:
- CBC: anemia, thrombocytopenia, variable WBC
- INR, PTT and fibrinogen, which are very important in APL because it associates with DIC
- Increased LDH, increased uric acid, increased phosphate released by leukemic blasts, increased K and decreased Ca2+, all markers of TLS
- Baseline renal and liver function tests
- Peripheral blood film: circulating blasts with Auer rods are pathognomonic for AML, and hypergranular promyelocytes point at APL
- Bone marrow aspirate for the definitive diagnosis, with a blast count over 20% in AML where normal is under 5%